Axel Meyer

Dr. Axel Meyer


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AMAxel Meyer
Axel Meyer
TFThomas Feldsien
Thomas Feldsien
MMMario Mezler
Mario Mezler
CUChristopher Untucht
Christopher Untucht
RVRamakrishna Venugopalan
Ramakrishna Venugopalan
DLDidier R. Lefebvre
Didier R. Lefebvre
The blood-brain barrier (BBB) is a major hurdle for the development of systemically delivered drugs against diseases of the central nervous system (CNS). Because of this barrier there is still a huge unmet need for the treatment of these diseases, despite years of research efforts across the pharmaceutical industry. Novel therapeutic entities, such as gene therapy and degradomers, have become increasingly popular in recent years, but have not been the focus for CNS indications so far. To unfold their full potential for the treatment of CNS diseases, these therapeutic entities will most likely have to rely on innovative delivery technologies. Here we will describe and assess approaches, both invasive and non-invasive, that can enable, or at least increase, the probability of a successful drug development of such novel therapeutics for CNS indications.

9 February 2021 in Nanoscale Advances
Verified
Journal Article
Open access
PDF file
DYDong Ye
Dong Ye
TZTina Zimmermann
Tina Zimmermann
VDVictoria Demina
Victoria Demina
SSSergey Sotnikov
Sergey Sotnikov
CRChristian L. Ried
Christian L. Ried
AMAxel Meyer
Axel Meyer
Hollow viral vectors, such as John Cunningham virus-like particles (JC VLPs), provide a unique opportunity to deliver drug cargo into targeted cells and tissue. Current understanding of the entry of JC virus in brain cells has remained insufficient. In particular, interaction of JC VLPs with the blood–brain barrier (BBB) has not been analyzed in detail. Thus, JC VLPs were produced in this study for investigating the trafficking across the BBB. We performed a carotid artery injection procedure for mouse brain to qualitatively study JC VLPs' in vivo binding and distribution and used in vitro approaches to analyze their uptake and export kinetics in brain endothelial cells. Our results show that clathrin-dependent mechanisms contributed to the entry of VLPs into brain endothelial cells, and exocytosis or transcytosis of VLPs across the BBB was observed in vitro. VLPs were found to interact with sialic acid glycans in mouse brain endothelia. The ability of JC VLPs to cross the BBB can be useful in developing a delivery system for transport of genes and small molecule cargoes to the brain.

22 May 2026 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
LMLaura S. Mahl
Laura S. Mahl
AMAxel Meyer
Axel Meyer
Tunicamycin induces endoplasmic reticulum (ER) stress by inhibiting N-glycosylation of newly synthesized proteins, leading to accumulation of misfolded proteins in the ER. This activates the unfolded protein response (UPR), a conserved adaptive pathway aimed at restoring proteostasis. A key mediator of this response is the kinase PERK which activates a signal cascade that leads to a global reduction in translation, while selectively enhancing the expression of stress-associated genes. This PERK-mediated response also constitutes a major arm of the integrated stress response (ISR). Under persistent ER stress, these response pathways may trigger pro-apoptotic programs in addition to adaptive responses. In this study, we used next-generation RNA sequencing to profile transcriptional changes in peripheral blood mononuclear cells (PBMCs) after 24 h of tunicamycin exposure, alone or with the PERK inhibitor GSK2606414 or the eIF2B activator ISRIB, to assess stress responses at distinct regulatory points within the PERK-ISR pathway. Key findings were validated by qRT-PCR, and pathway enrichment analysis was performed using the Gene Ontology Resource and the Reactome database. ER stress altered gene expression, with 4.80% of genes upregulated and 12.67% downregulated. GSK2606414 suppressed a broader subset of tunicamycin-induced genes than ISRIB. However, both inhibitors effectively reversed upregulation of the top two stress-responsive genes, TNC and WNT5A. Pathway enrichment analysis revealed overrepresentation of pathways related to ER stress responses, unfolded protein homeostasis, ER chaperone complex assembly, amino acid biosynthesis and interconversion, and aminoacyl-tRNA synthetase-mediated protein translation. These findings provide mechanistic insights into chronic ER stress in PBMCs and identify WNT5A and TNC as candidate biomarkers, pending further validation.

1 July 2017 in Neuropharmacology
Verified
Journal Article
Closed access
AMAxel Meyer
Axel Meyer
CUChristopher Untucht
Christopher Untucht
GTGeorg C. Terstappen
Georg C. Terstappen